Roche is licensing out part of its cancer platform to Chinese biotech Innovent Biologics.
Innovent gains nonexclusive access to the Swiss major’s cell therapies and bispecific antibodies for both blood and solid cancers.
Under the pact, details of which were fairly thin, Innovent will “create, develop, manufacture, and commercialize the products,” while Roche retains an option to license each product for development and sale outside of China.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,